Skip to main content
. Author manuscript; available in PMC: 2012 Jan 23.
Published in final edited form as: Clin Cancer Res. 2011 Jan 1;17(1):122–133. doi: 10.1158/1078-0432.CCR-10-0253

Figure 3. Treatment with SNX-5542 induces inhibition of tumor growth in GTL-16 and EBC-1 xenograft models.

Figure 3

Four to 6-week old athymic nu/nu BALB/c mice with established GTL-16 and EBC-1 xenografts (5 per group) were randomized to treatment with SNX-5542 or the control group. Mice were treated with SNX-5542, an orally bioavailable prodrug of SNX-2112, by oral gavage on a Monday – Wednesday – Friday schedule. The tumor volume was measured as described in Materials and Methods. Data are depicted as mean ± 68% CI to account for right-skewed data distribution. This would correspond to a depiction as mean ± SE in the case of normal distribution. P-values are from the regression model. The control arm of the EBC-1 xenograft model had to be discontinued after day 22 because of excessive tumor growth and ulceration of the tumors.